Scleromyxedema Managed With High-Dose Intravenous Immunoglobulin and Bortezomib–Dexamethasone: A Case Report [PDF]
Case Reports in Oncological MedicineScleromyxedema is a rare, chronic cutaneous mucinosis marked by widespread waxy papules and potential extracutaneous involvement. This case report discusses the management of a 48-year-old female diagnosed with scleromyxedema, who initially partially ...
Darren Wijaya +3 more
doaj +3 more sources
Monoclonal Gammopathies of Clinical Significance—Scleromyxedema: A Case Report and Literature Review [PDF]
Clinical Case ReportsScleromyxedema is an uncommon, chronic connective tissue disorder with an obscure etiology. It is distinguished by fibromyxoid skin lesions and elevated serum monoclonal immunoglobulin levels.
Shanshan Liang +4 more
doaj +3 more sources
Skin‐Colored Papules on the Face and Chest of a Female Patient [PDF]
Clinical Case ReportsScleromyxedema is an unpredictable but progressive disease and can be lethal due to systemic involvement if not diagnosed timely. Hence, we require a keen observational clinical eye to diagnose the condition from its differentials, along with further ...
Mehdi Ghahartars +3 more
doaj +3 more sources
Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives. [PDF]
Exp DermatolJAK inhibitors are used to treat various inflammatory skin diseases. However, systemic formulations are associated with an increased risk of major adverse events.
Spadafora M +5 more
europepmc +4 more sources
Scleromyxedema without Paraproteinemia: Treatment with Thalidomide and Prednisolone [PDF]
Case Reports in Dermatology, 2016 Scleromyxedema is a rare and distinctive variant of cutaneous mucinoses of unknown etiology. It is presenting with generalized papular eruption and sclerodermoid induration. Numerous treatment modalities have been reported to produce partial or permanent
Sara Saniee, Ghazaleh Davarnia
doaj +2 more sources
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2, Scleromyxoedema and scleroedema [PDF]
Journal of the European Academy of Dermatology and Venereology, Volume 38, Issue 7, Page 1281-1299, July 2024.The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement ...
Knobler, Robert, Sunderkötter, Cord
core +8 more sources
Treatment of a Complex Case of Scleromyxedema Using a Novel Intravenous Immunoglobulin Preparation [PDF]
Case Reports in DermatologyIntroduction: We provide a case report on a patient with scleromyxedema treated with high-dose intravenous immunoglobulins (IVIgs) who reported less fatigue and fewer headaches after transitioning to Yimmugo, a novel IVIg preparation. Scleromyxedema is a
Anastasia Sophie Vollmer +3 more
doaj +2 more sources
Lichen myxedematosus associated with monoclonal gammopathy of undetermined significance: A case report and literature review [PDF]
Frontiers in Medicine, 2023 Lichen myxedematosus (LM) is an idiopathic cutaneous mucinosis disorder, and monoclonal gammopathy of undetermined significance (MGUS) is a preneoplastic plasma cell disease with a monoclonal increase in globulin.
Hua Huang, Shen-Xian Qian
doaj +2 more sources
Early onset of scleromyxedema Arndt‐Gottron associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins [PDF]
Clinical Case Reports, 2022 Arndt‐Gottron (S‐AG) syndrome or scleromyxedema is a scarce disease characterized by a generalized papular and sclerodermoid eruption and systemic manifestations that can lead to significant morbid‐mortality.
Asma Kefi +3 more
doaj +2 more sources
Acta Medica Iranica, 1996 Scleromyxedema is a rare, chronic, progressive, fibromucinous disorder of unknown etiology, characterized by lichenoid waxy papules and firm induration of skin of trunk, face, forearm and hands; fibroblast proliferation and mucin deposition in the upper ...
Z. Safaii Naraghi. +1 more
doaj +3 more sources